New research in the June 2024 issue of Journal of the National Comprehensive Cancer Network highlights a promising approach for alleviating distress, enhancing quality of life, improving physical function, and reducing fatigue ...
Jun 11, 2024
0
65
There is no significant association between exposure to immunosuppressive therapies and development of incident cancers among patients with inflammatory bowel disease (IBD) and a history of cancer, according to a study published ...
Jun 11, 2024
0
0
Investigators from UCLA Health found using artificial intelligence to help map out the boundaries of cancerous prostate tissue can significantly reduce the risk of underestimating the extent of prostate cancer—an advancement ...
Jun 11, 2024
0
0
A new editorial paper was published in Oncoscience on May 6, 2024, titled, "Restoring our ubiquitination machinery to overcome resistance in cancer therapy."
Jun 10, 2024
0
0
Two genes working in tandem play a critical role in shaping the identity and behavior of prostate cancer cells and their response to treatment, UT Southwestern Medical Center researchers report.
Jun 5, 2024
0
0
In a recent study led by Suresh Ramalingam, MD, executive director of Winship Cancer Institute of Emory University, a new drug has shown remarkable promise in treating patients with a specific type of advanced lung cancer.
Jun 5, 2024
0
19
A team of UC Davis Health researchers has discovered that a common anti-inflammatory drug, mesalamine, can replace the work of good bacteria in fighting the nasty fungus Candida albicans in the gut.
Jun 4, 2024
0
57
Advanced clear cell renal cell carcinoma (ccRCC) is a deadly form of kidney cancer with few treatment options; even with new immunotherapies, only around one in 10 patients ultimately survive.
Jun 4, 2024
0
0
Treatment resistance caused by cancer cell plasticity constitutes a major challenge in the treatment of prostate cancer. A recent study from the University of Eastern Finland Institute of Biomedicine published in Nucleic ...
Jun 3, 2024
0
1
Immunotherapy before surgery for patients with metastatic melanoma appears to be especially successful. Some 59% of patients respond so well to this therapy that adjuvant treatment is no longer needed, according to the results ...
Jun 3, 2024
0
1
